Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00828204 · ClinicalTrials.gov registry record · Phase 3
Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects
A Phase 3 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 3
- Development phase
- 95
- Enrollment target
NCT00828204 is a Phase 3 study that has completed, run by Biogen. The registered enrollment target is 95 participants.
The verdict
NCT00828204, a Phase 3 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 95 participants
- Enrollment target
Study Summary
The primary objective of the study was to evaluate the safe and effective use of the single-use autoinjector for the intramuscular (IM) delivery of liquid Avonex® (interferon beta-1a) in participants with multiple sclerosis (MS).
Interventions
- DEVICE single-use autoinjector with a prefilled liquid Avonex syringe
- DEVICE Avonex prefilled syringe via manual IM injection
- DRUG BG9418 (interferon beta-1a)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00828204
The ClinicalTrials.gov registry entry for NCT00828204 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which single-use autoinjector with a prefilled liquid Avonex syringe is the first listed.
NCT00828204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00828204 about?
NCT00828204 is a clinical study titled "Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects". The primary objective of the study was to evaluate the safe and effective use of the single-use autoinjector for the intramuscular (IM) delivery of liquid Avonex® (interferon beta-1a) in participants with multiple sclerosis (MS).
What is the current status of trial NCT00828204?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 95 participants. The study started on 2009-01. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00828204?
The interventions under investigation include: single-use autoinjector with a prefilled liquid Avonex syringe (DEVICE), Avonex prefilled syringe via manual IM injection (DEVICE), BG9418 (interferon beta-1a) (DRUG).
Who is sponsoring clinical trial NCT00828204?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.